Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® ...

Gilead Sciences, Inc. GILD obtained approval FDA approved for the label expansion of breast cancer drug Trodelvy (sacituzumab ...

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences Inc.’s GILD Trodelvy (sacituzumab govitecan-hziy) ...

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening ...

The FDA has approved sacituzumab govitecan-hziy as first-line therapy for adults with unresectable locally advanced or ...

The game is on for TROP2 antibody-drug conjugates in first-line triple-negative breast cancer. | Less than a month after an approval for Daiichi Sankyo and AstraZeneca’s Datroway for front-line TNBC ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 25, Gilead ...

Trodelvy (sacituzumab govitecan-hziy) is a brand-name drug prescribed for certain breast cancers. It’s given as an intravenous (IV) infusion by a healthcare professional. The dosage can vary depending ...

Trodelvy dosing is 10 mg/kg IV on days 1 and 8 of 21-day cycles, continued until progression or unacceptable toxicity; pembrolizumab schedules follow prescriber determination. Safety requires ...

Trodelvy is a prescription medication given by IV infusion to treat specific types of breast cancer. The dosage is calculated based on body weight in kilograms (kg). Treatment with Trodelvy involves a ...

Since Gilead Sciences unveiled a $21 billion buyout of Immunomedics centered on Trodelvy, industry watchers have been busy crunching the numbers. Now, after seeing new data, one analyst sees broad ...

The European Commission (EC) has granted marketing authorization for US biotech Gilead Sciences Trodelvy (sacituzumab ...